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Background
Gastric cancer is a neoplasm with a poor prognosis, often
diagnosed in advanced stage of disease, specially in eld-
erly patients. Neo-adjuvant chemotherapy may increase
the possibility of complete surgical resection, improving
progression-free and overall survival (five-years survival of
36% compared with 23% of patients treated by surgery
alone) as shown in the MAGIC Trial by Cunningham et al.
Materials and methods
Since November 2006, at our Institute, selected patients
affected by gastric adenocarcinoma were enrolled in a pro-
gram of peri-operative chemotherapy; six of them were
over 70 years old. The neoplasia was diagnosed and staged
by gastroscopy, endoscopic ultrasonography and total
body 18FDG-PET-CT. Inclusion criteria were: cT2N+M0 or
cT3-4N × M0, age <75, Karnofsky Performance Status
>60%, no hepatic, renal and bone marrow failure (creati-
nine <1.5 mg/dL; clearance creatinine >50 ml/L; total
bilirubin <2 mg/dl; white blood cells >3500 mm3; plate-
lets >140000/mm3). The patient underwent three cycles
of pre-operative chemotherapy with Epirubicine, Cispla-
tin and 5-Fluorouracil (ECF) as MAGIC Trial showed.
After every cycle hepatic, renal, bone marrow and cardiac
functionality were evaluated. Fifteen days after the third
pre-operative ECF cycle the patients underwent endo-
scopic ultrasonography and total body 18FDG-PET-CT to
evaluate the tumor response to chemotherapy, then they
underwent surgery. Thirty day after surgery they started
the first of the three post-operative ECF. One patient just
finished pre-operative chemotheraphy and she will be
operated in four weeks. Clinical and pathological charac-
teristics of patients are summerized in Table 1.
Results
All patients completed the pre-operative chemotherapy
without toxicity. Three patients underwent D2 total gast-
rectomy, one patient D2 subtotal gastrectomy and
another patient, with diffuse pattern adenocarcinoma and
lymph node metastases (N3), underwent D1 total gastrec-
tomy. No peri- and post-operative mortality and morbid-
ity were observed. Chemotherapy was started one month
after surgery in all five patients. During post-operative
chemotherapy one patient developed right subclavian
vein thrombosis (close to the site of port-a-cath); in one
patient the second cycle of post-operative chemotherapy
was stopped due to renal failure. The patient affected by
liver metastases and the one with N3 lymph node metas-
tases died respectively 18 and 11 months after surgery
because of disease progression. The other three patients
are in good conditions with no clinical and radiological
evidence of recurrences.
Conclusion
Although surgical resection remains the key component
in the treatment of gastric cancer, improved outcome
depends on multidisciplinary treatments. Neo-adjuvant
chemotherapy may be a valid option in downstaging the
primary tumor and increasing resectability rates, as shown
by MAGIC Trail. Our little experience shows that peri-
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operative chemotherapy with ECF has low toxicity and it
may be chosen in elderly affected by locally advanced gas-
tric adenocarcinoma.











1 M 74 Antrum Intestinal T3 N+ M0 T2 N+ M0 D2 gastrectomy, 
splenectomy, hepatic wedge 
resections
T3 N1 M1 3
2 F 71 Small curve Intestinal T3 N+ M0 T2b N+ M0 D3 gastrectomy T2b N1 M0 3
3 M 75 Angulus Diffuse T3 N0 M0 T2 N0 M0 D2 gastrectomy T2a N0 M0 2
4 M 74 Body Diffuse T3 N+ M0 T3 N+ M0 D1 gastrectomy T3 N3 M0 3
5 F 75 Angulus Intestinal T3 N+ M0 T2 N0 M0 D2 gastroresection T1 N0 M0 1
6 F 71 Oesofagus-gastric 
junction (Siewert III)
Intestinal T3 N+ M0 T2 N+ M0 - - -Page 2 of 2
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